Amneal Pharmaceuticals, Inc.

Good morning, and welcome to today's Amniel Pharmaceuticals Investor Call. I will now turn the call over to Amniel's Head of Investor Relations, Tony DiMaio.

Good morning, and thank you for joining Amniel Pharmaceuticals Investor Call. This morning, we issued a press release announcing Amniel agrees to acquire Kashif Bioscientists and reporting preliminary Q1 results. The press release and presentation are available at amuel.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled Cautionary Statements on forward-looking statements for factors that may impact future performance. We also discussed non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the press release and presentation. On the call today are Chirag and Shintu Patel, co-founders and co-CEOs, Tasos Konideris, CFO, and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag. Thank you, Tony.

Today is a defining moment for MNEO. This morning, we announced that MNIL agrees to acquire Kashuk Biosciences, creating a fully integrated global biosimilars leader and positioning MNIL to become the number one affordable medicines company in the United States. We have long said this was our goal, and today we're showing exactly how to get there. Turning to slide three. I'll begin the call by discussing the strategic fit of the acquisition and the remarkable biosimilar opportunity ahead. Shintu will share more about Kashiv, our combined capabilities, and the robust biosimilar portfolio we will have. Tasuz will discuss the transaction, our financial outlook, and MNIL's very strong first quarter results, which we pre-announced this morning. At a high level, Q1 marked another consecutive quarter of strong top and bottom line growth, with revenue up 4%, adjusted EBITDA up 19%, and EPS up 29%. Our strong start of the year, combined with growth of existing and new products, gives us confidence to raise our standalone guidance for 2026. This consistent performance is something investors have come to expect from MNIL and something we take great pride in. On slide four, we provide an executive summary of this combination. First, this is a highly strategic transaction that creates fully integrated global biosimilar leader. This unlocks direct access to more than $300 billion of worldwide biologic loss of exclusivity over the next decade by bringing together Kashif's deep R&D and manufacturing capabilities with our proven commercial scale. This combination builds on a long standing partnership that significantly reduces execution risk. Second, this combination creates immediate scale in biosimilars. We expect multiple launches each year going forward, supported by a robust pipeline of more than 20 biosimilars programs. Third, this adds biosimilars as a key growth pillar within affordable medicines. The transaction further diversifies our business and extends our growth profile well into 2030s. while also creating a footprint to expand internationally over time. And fourth, the deal is structured to create value from day one. With a balanced mix of upfront consideration, performance-based milestones, we expect significant financial synergies, and we maintain a disciplined financial profile with a clear path to be leveraged to below 3x by 2028.